1 / 7

Binnopharm is your trusted Sherpa * in Russian pharmaceutical industry

Binnopharm is your trusted Sherpa * in Russian pharmaceutical industry.

gunda
Download Presentation

Binnopharm is your trusted Sherpa * in Russian pharmaceutical industry

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Binnopharm is your trusted Sherpa* in Russian pharmaceutical industry *The Sherpa (Tibetan:ཤར་པ། "eastern people", from shar "east" + pa "people") are an ethnic group from the most mountainous region of Nepal, high in the Himalayas. A Sherpa is the personal representative of a head of state of government who prepares an international summit. This reduces the amount of time and resources required at the negotiations of the heads of state at the final summit. IV Russian-Indian forum on trade and investments. December20th , 2010 Maxim G. Uvarov CEO, CJSC “Binnopharm”

  2. The market of pharmaceutical products in Russia is attractive and possesses a huge potential for growth, at least double, concerning the countries of the East Europe. Main challenge Medical products consumption per capita in 2009, $ « In 10 years the volume of medical products sales in our country will amount to 1,5bln RUB. It is a very significant figure. Actually we should move to the Central European level of medical products consumption that naturally should be finally converted both in life span and its quality.» USA France Japan Germany Canada England Russia Japan USA Poland $250 $450 $700 Dmitry A. Medvedev,at the meeting of a Committee on Modernization and technological Development of Economy of Russia in Pskov (Vladimirskaya region), August 31st ,2009

  3. Development trend of pharmaceutics opens opportunities for investments in Russia and lunching Joint Ventures Imported pharmaceutics Financial resources of the public Structure of RF pharmaceutical market by origin* Structure of RF pharmaceutical market by consumption* Home-produced pharmaceutics Financial resources of the state budget 1500 bln rub. 450bln. 50% CAGR 2009-2020 +9% 400 bln. rub. CAGR 2004-2009 +31% 1050 bln. Growth by 10 times! CAGR 2009-2020 +24% 50% full cycle 300bln 79% 137 bln. rub. 76% 24% 100bln. 21% in bulk 2004 2009 2020 * Retail prices • Less then 5 % of drugs in RF are produced by complete cycle, there are plans to reach it up to 50%. • During the next 10 years state purchasing (state budget) is expected to increase by 10 times • There is much resistance in entering this market segment Challenge

  4. Binnopharm • SISTEMA is the largest public diversified company in Russia owns 100% Binnopharm, invests in the largest Russian GMP pharmaceutical plant in Moscow • Binnopharm today : • is a relatively young, but upcoming pharmaceutical company • wins all the state tender for producing large-scale lots of vaccine from Hepatitis B • Russian Prime-minister V.V. Putin together with the government delegation opens production facility in Moscow • The “historical” decision is made by the government – to create the biopharmaceutical cluster BioCity on the basis of Binnopharm production facility and including it in the Free Economic Zone

  5. Cluster Biocity became the source of new R&D products, orders, personnel, income (including tax free) • The first BioPharmaceutical cluster in Moscow combining science, education and production for development and commercialization innovative products in oncology, hematology, infection and respiratory • Several objects will appear • Research center in Moscow Government University • Development center • Free Economical Zone About the project • The largest University and the largest biopharmaceutical faculty in Russia • The largest Russian GMP biopharmaceutical plant • >10 Moscow Science Centers – the largest in Russia • >10 companies Participants Current Status • The first project «Artificial Skin» was approved by Moscow & Russian Government and first grant for $5mln. was approved and received

  6. New Joint Ventures in the cluster with Binnopharm • «British pharmaceutical company GlaxoSmithKline (GSK) announced a major deal in Russia today as Business Secretary Dr Vince Cable opened bilateral trade talks with Russian Deputy Prime Minister and Finance Minister Alexey Kudrin»* • «GlaxoSmithKline announced a deal with Binnopharm that will allow the Russian drugmaker to manufacture and market GlaxoSmithKline's vaccines in its domestic market. AbbasHussain, head of emerging markets and Asia Pacific for GlaxoSmithKline, said the «agreement is an example of the flexible approach we are taking to make innovative vaccines more available in emerging markets through local partnerships.»… • …The two companies noted that «the local manufacture of these vaccines should help Russia to modernise its National Immunisation Calendar in the future.»**

  7. Next project that gets Russian Government Finance and Market Access will be definitely with an Indian partner. Binnopharm is your trusted Sherpa in Russian pharmaceutical industry. From Russia with love… CJSC BINNOPHARM Russia 124460, 3/1, 4th Zapadny proezd, Zelenograd, Moscow Tel./fax:+7 (495) 510-3288 e-mail: info@binnopharm.ru web: http://www.binnopharm.ru

More Related